Abstract
99mTc-labelled hexamethylpropylene amine oxime (HMPAO) is a lipophilic compound with a neutral charge which reflects tumor blood flow and has been previously investigated to estimate brain blood flow. In this study, we attempted to use99mTc-HMPAO for the evaluation of 18 patients with histologically proven primary lung carcinoma. The eight surgical specimens revealed that viable carcinoma cells were present when the99mTc-HMPAO accumulated in the tumor, however, extensive tumor necrosis was observed when defective or ring like uptake was seen in the tumor. Qualitative study revealed that when perfusion defects were observed corresponding to the tumor, the possibility of squamous cell carcinoma or large cell carcinoma was high instead of adenocarcinoma. Quantitative analysis revealed that the uptake ratio was statistically different between adenocarcinoma (1.6±0.1) and squamous cell carcinoma (1.2±0.4) (P<0.05), between squamous cell carcinoma and large cell carcinoma (0.9±0.1) (P<0.05), and also between adenocarcinoma and large cell carcinoma (P<0.01). In conclusion,99mTc-HMPAO may be useful for the evaluation of patients with primary lung carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Babich JW, Keeling F, Flower MA, Repetto L, Whitton A, Fielding S, Fullbrook A, Ott RJ, McCready VR (1988) Initial experience with Tc-99m-HM-PAO in the study of brain tumors. Eur J Nucl Med 14:39–44
Botsch H (1987) Anreicherung von Tc-99m HMPAO in einer Melanom Metastase und im Myokard des linken Ventrikels. Nucl Compact 18:151–152
Edwards CL, Hayes RL, Nelson B (1972) The “normal” Ga-67 scan. J Nucl Med 13:428–429 (abstr)
Hammersley PAG, McCready VR, Babich JW, Coghlan G (1987) Tc-99m HMPAO as a tumour blood flow agent. Eur J Nucl Med 13:90–94
Hoshi H, Jinnouchi S, Sameshima M, Uwada O, Watanabe K (1988) Tc-99m hexamethylpropylene-amine oxime (HM-PAO) uptake in a bone metastasis. Clin Nucl Med 13:595–598
Langen KJ, Herzog H, Rota E, Roosen N, Wieler H, Kiwit J, Kuwert T, Storch-Becker A, Feinendengen L (1987) Tomographic studies of rCBF with Tc-99m HM-PAO in comparison with PET in patients with primary brain tumors. Neurosurg Rev 10:23–24
Lindegaad MW, Skretting A, Hager B, Watne K, Lindergaad KF (1986) Cerebral and cerebellar uptake of Tc-99m-(d,l)-hexamethyl-propyleneamineoxime (HM-PAO) in patients with brain tumor studied by single photon emission computerized tomography. Eur J Nucl Med 12:417–420
McCready VR, Tate D, Keeling F, Hammersley PAG, Davidson T, Ott RJ, Babich J, Flower M (1988) Technetium-99m HMPAO for the detection of tumours and measurement of blood flow. Br J Rad 60:734 (abstr)
Nakamura K, Tukatani Y, Kubo A, Hashimoto S, Terayama Y, Amano T, Goto F (1989) The behavior of Tc-99m hexamethylpropyleneamineoxime (Tc-99m-HM-PAO) in blood and brain. Eur J Nucl Med 15:100–107
Notwotnik DP, Canning LR, Cumming SA, Harrison RC, Higley B, Nechvatal G, Pickett RD, Piper IM, Bayne VJ, Foster AM, Weisner PS, Neirinckx RD (1985) Development of a Te-99mlabelled radiopharmaceuticl for cerebral blood flow imaging. Nucl Med Commun 6:499–506
Obata Y, Sakuma S, Saito H, Noguchi E, Abe T, Nishino M, Fugiki Y, Kumano N (1984) Clinical application of the digital gamma camera with twin opposed large rectangular detectors. Jpn J Nucl Med 21:979–983
Podreka I, Suess E, Goldenberg G, Steiner M, Brucke Muller C, Lang W, Neirinckx RD, Deecke L (1987) Initial experience with technetium-99m HMPAO brain SPECT. J Nucl Med 28:1657–1666
Tait D, McCready VR, Ott RJ (1987) HM-PAO assessment of human tumour perfusion. Eur J Cancer Clin Oncol 23:789–793
Weishner PS, Neirinckx RD (1985) Development of a Tc-99mlabelled radiopharmaceutical for cerebral blood flow imaging. Nucl Med Commun 6:499–506
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oshima, M., Itoh, K., Okae, S. et al. Evaluation of primary lung carcinoma using technetium 99m-hexamethylpropylene amine oxime: preliminary clinical experience. Eur J Nucl Med 16, 859–864 (1990). https://doi.org/10.1007/BF01280252
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01280252